RGD Reference Report - Functional role of soluble receptor for advanced glycation end products in stroke. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Functional role of soluble receptor for advanced glycation end products in stroke.

Authors: Tang, SC  Wang, YC  Li, YI  Lin, HC  Manzanero, S  Hsieh, YH  Phipps, S  Hu, CJ  Chiou, HY  Huang, YS  Yang, WS  Mattson, MP  Arumugam, TV  Jeng, JS 
Citation: Tang SC, etal., Arterioscler Thromb Vasc Biol. 2013 Mar;33(3):585-94. doi: 10.1161/ATVBAHA.112.300523. Epub 2013 Jan 3.
RGD ID: 8696004
Pubmed: PMID:23288172   (View Abstract at PubMed)
DOI: DOI:10.1161/ATVBAHA.112.300523   (Journal Full-text)

OBJECTIVE: Little is known about the involvement of the soluble form of receptor for advanced glycation end products (sRAGE) in acute ischemic stroke (IS). Here, we aim to identify the role of plasma sRAGE and high mobility group box 1 (HMGB1) in imaging-confirmed IS patients, as well as mice subjected to focal ischemic stroke. METHODS AND RESULTS: IS patients were recruited and plasma samples were collected for the measurement of sRAGE and HMGB1 after stroke. The relation of sRAGE and HMGB1 with acute IS was also investigated in a C57BL/6J mouse model of focal ischemic stroke and primary cortical neurons subjected to oxygen and glucose deprivation. Plasma levels of sRAGE and HMGB1 were both significantly increased within 48 hours after IS, and the sRAGE level was an independent predictor of functional outcome at 3 months poststroke. Immunoprecipitation assays revealed that the binding of plasma HMGB1 to sRAGE increased progressively after IS both in patients and mice. Administration of recombinant sRAGE significantly reduced infiltrating immune cells and improved the outcome of injury in mice, protected cultured neurons against oxygen and glucose deprivation-induced cell death, and ameliorated the detrimental effect of recombinant HMGB1. CONCLUSIONS: Early poststroke plasma sRAGE may play a protective role in IS by capturing HMGB1. Hence, recombinant sRAGE is a potential therapeutic agent in acute IS.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
cerebral infarction  IEP 8696004; 8696004protein:increased expression:plasmaRGD 
cerebral infarction  ISOAGER (Homo sapiens)8696004; 8696004protein:increased expression:plasmaRGD 
cerebral infarction  ISOHMGB1 (Homo sapiens)8696004; 8696004protein:increased expression:plasmaRGD 
transient cerebral ischemia  ISOAger (Mus musculus)8696004; 8696004protein:increased expression:brain and plasmaRGD 
transient cerebral ischemia  IEP 8696004; 8696004protein:increased expression:brain and plasmaRGD 
transient cerebral ischemia  ISOHmgb1 (Mus musculus)8696004; 8696004protein:increased expression:brain and plasmaRGD 

Objects Annotated

Genes (Rattus norvegicus)
Ager  (advanced glycosylation end product-specific receptor)
Hmgb1  (high mobility group box 1)

Genes (Mus musculus)
Ager  (advanced glycosylation end product-specific receptor)
Hmgb1  (high mobility group box 1)

Genes (Homo sapiens)
AGER  (advanced glycosylation end-product specific receptor)
HMGB1  (high mobility group box 1)


Additional Information